Day

January 7, 2019
The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate (ORR) of 83.3%, with a very good partial response (VGPR) or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma, according to initial results from a phase I study presented at theĀ 2018 ASH Annual Meeting.1 In the preliminary results from the...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand